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Abstract
Background: Akt is a critical mediator of developmental skeletal muscle growth. Treatment with a soluble ActRIIB fusion
protein (ActRIIB-mFc) increases skeletal muscle mass and strength by inhibiting myostatin and related peptides. Recent in
vitro studies have suggested that Akt signaling is necessary for the ability of ActRIIB inhibition to induce muscle
hypertrophy. Thus, we hypothesized that mice deficient in either Akt1 or Akt2 would not respond to in vivo inhibition of
ActRIIB with ActRIIB-mFc treatment.
Methodology and Principal Findings: We analyzed body composition and muscle parameters in wild-type C57BL/6J and
Akt1 and Akt2 knockout mice, and compared the responses to blockade of ActRIIB signaling via ActRIIB-mFc treatment.
Mice lacking Akt1 or Akt2 had reduced muscle mass, grip strength and contractile force. However, deficiency of Akt1 or Akt2
did not prevent the ability of ActRIIB-mFc treatment to induce muscle hypertrophy, or increase grip strength and contractile
force. Akt1 and Akt2 deficient mice responded similarly as wild type mice to ActRIIB-mFc treatment by increasing fiber size.
Conclusions and Significance: Akt1 and Akt2 are important for the regulation of skeletal muscle mass and function.
However, these Akt isoforms are not essential for the ability of ActRIIB inhibition to regulate muscle size, fiber type, strength
or contractile force.
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Introduction
Skeletal muscle adapts to environmental stimuli and alters its
mass accordingly. New myofilaments are added to existing
myofibrils through an increase in protein synthesis under the
control of mechanical load, nutrients and hormones. Signaling
through the phosphatidylinositol 3-kinase (PI3K)/Akt pathway
increases protein synthesis [1,2]. Akt is sufficient to induce muscle
hypertrophy as demonstrated by muscle-specific expression of a
constitutively active form of Akt [3]. Three Akt isoforms (Akt1/2/
3) have been identified in mice and humans, and implicated in the
regulation of growth and metabolism [4,5]. Germline ablation of
Akt1 results in a proportional reduction in body size [6,7,8]. In
contrast, conditional Akt1 overexpression in muscle resulted in
muscle hypertrophy and increase in strength [9,10]. Disruption of
Akt2 in mice resulted in insulin resistance, hyperglycemia,
hyperinsulinemia, and glucose intolerance [11,12]. As with Akt1,
mice lacking Akt2 develop a mild growth deficiency [11,12].
Deficiency of both Akt1 and Akt2 resulted in multiple develop-
mental defects including muscle atrophy [13].
Another key mediator of muscle size is the activin receptor type
IIB (ActRIIB) [14]. ActRIIB is a type II transforming growth
factor (TGF)-b superfamily receptor that is emerging as a key
player in the regulation of muscle size and strength [15,16].
Ligands, including myostatin and GDF-11, bind to the ActRIIB
leading to phosphorylation and nuclear translocation of Smad2/3,
which mediates muscle atrophy [17]. Inhibition of ActRIIB
signaling can be achieved by genetically overexpressing regulatory
proteins (such as follistatin), which binds and inhibits endogenous
TGFb superfamily ligands [18,19]. Other methods for inhibiting
ActRIIB include expression of a dominant-negative form of
ActRIIB [19] or postnatal injection of a decoy ActRIIB receptor
[15,16]. These methods result in a dramatic increase in muscle
mass, more than what is seen in myostatin deficiency alone,
indicating that more than one ActRIIB ligand is important for the
control of muscle size [16,19,20].
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demonstrated a dominant role of Akt signaling in the regulation of
myocellular hypertrophy resulting from inhibition of ActRIIB
[10,21,22,23,24,25]. It is unknown, however, whether the
interaction between Akt and ActRIIB signaling is responsible for
the resulting hypertrophy in vivo. We have previously shown that
treatment with a decoy ActRIIB soluble receptor (ActRIIB-mFc)
increased muscle size and contraction force [15,26]. We
hypothesized that deficiency of Akt1 or Akt2 would prevent the
in vivo effects of ActRIIB inhibition on muscle.
Results
Effects of Akt deficiency and ActRIIB blockade on body
composition
We first performed immunoblotting on lysates from gastrocne-
mius muscles to assess the effects of ActRIIB-mFc on ActRIIB
signaling on the levels of total Akt and phospho-Akt (Ser473).
ActRIIB-mFc treatment increased total Akt significantly (Fig. 1).
The level of phospho-Akt increased slightly in response to
ActRIIB-mFc, but this was not significant (Figure 1).
We compared body composition among wild type (WT) and
Akt1 knockout (ko) and Akt2ko mice, and also examined the
effects of ActRIIB-mFc after 10 weeks. There was a significant
effect on body weight with respect to genotype (Figure 2A,
p=0.0008). Akt1ko mice weighed significantly less than WT
(14.1%, p=0.0265) and Akt2ko mice tended to weigh less than
WT (13.8%, p=0.0751). There was a significant effect on lean
mass (Figure 2B, p,0.01), and fat mass (Figure 2C, p,0.01) with
respect to genotype. Lean mass was 15% lower in Akt1ko mice as
compared to WT (Figure 2B, p,0.01) whereas Akt2ko mice were
not significantly different. Fat mass was 44% decreased in Akt2ko
mice as compared to WT mice (Figure 2C, p,0.05), whereas it
was unchanged in Akt1ko mice. The proportions of lean and fat
tissue were unchanged from WT in Akt1ko mice (WT lean:
78.361.7%, WT fat: 18.461.6%; Akt1ko lean: 76.961.5%,
Akt1ko fat: 20.561.9%). In contrast, Akt2ko mice had a
significant increase in percentage lean tissue and a decrease in
percentage fat (Akt2ko lean: 83.760.3%, fat: 12.160.4%, p,0.01
vs. WT for both) when compared to WT.
ActRIIB-mFc treatment had a significant effect on body weight
(120% in WT, 115% in Akt1ko, and 124% in Akt2ko. Figure 2A,
p,0.0001). In accordance with changes in body weight, lean mass
was significantly affected by treatment (Figure 2B, p,0.0001). Fat
mass tended to decrease with ActRIIB-mFc treatment in WT and
Akt1ko mice cohorts but increased in Akt2ko mice (Figure 2C,
p,0.05). With ActRIIB-mFc treatment, the proportions of lean
tissue significantly increased in WT and Akt1ko mice (WT:
84.360.3%; Akt1ko 82.360.7%, p,0.01 for both) while the
proportion of fat tissue decreased (WT: 12.360.4%; Akt1ko
16.061.2%, p,0.05 for both). In contrast, Akt2ko mice had no
change in body composition (Akt2ko lean: 84.460.7%, fat:
12.160.4%) with treatment.
Effects of Akt deficiency and ActRIIB blockade on muscle
structure
We examined the effects of Akt deficiency on various skeletal
muscles (Figures 3A–E). The weights of extensor digitorum longus
(EDL), gastrocnemius, anterior quadriceps, tibialis anterior, and
soleus were significantly affected by genotype (p,0.01 for all). The
mass of EDL, gastrocnemius, and anterior quadriceps was
significantly decreased in Akt1ko compared to WT (Figure 3A–
C). Akt2ko mice showed a decrease in EDL and gastrocnemius
mass (Figure 3A–B) and a 21% increase in soleus mass as
compared to WT (Figure 3E, p,0.01). Heart mass was
significantly affected by genotype (Figure 3F, p=0.0012). Akt1ko
heart mass was 20% lower than WT (p,0.05) but unaffected in
Akt2ko. ActRIIB-mFc treatment increased the weights of all
skeletal muscles measured (Figures 3A–E). Heart mass was
decreased in Akt1ko mice with treatment however not in WT or
Akt2ko mice (Figure 3F, p,0.05).
Next, we compared the effects of Akt deficiency and ActRIIB
blockade on EDL and soleus muscles as examples of glycolytic
versus oxidative muscles, respectively. The mean cross sectional
area (CSA) of EDL was significantly altered with genotype (WT:
1.7560.14 mm
2, Akt1ko: 1.2260.07 mm
2, Akt2ko: 1.2560.13
mm
2,p ,0.0001). There was a shift to the left in the distribution of
EDL fiber CSA in Akt1ko and Akt2ko mice (Figure 4A) as
represented by a decrease in mean EDL fiber CSA (Figure 4B,
p,0.0001 for both Akt1ko and Akt2ko vs. WT). The number of
EDL fibers was affected by genotype (Figure 4C, p,0.01) however
direct comparisons to WT were non-significant. ActRIIB-mFc
treatment increased the mean EDL fiber CSA and resulted in a
right shift in the distribution of fibers in WT, Akt1ko and Akt2ko
mice (Figure 4A). There was no significant change in the total
number of EDL muscle fibers following ActRIIB-mFc treatment
(Figure 4C). These data confirmed that ActRIIB-mFc induced
EDL muscle hypertrophy and not hyperplasia [15].
In contrast to EDL, Akt deficiency did not change the soleus
CSA (WT: 1.6460.27, Akt1ko: 1.4860.10, Akt2ko: 1.5660.04
mm
2) or total number of fibers (WT: 896.5667.5, Akt1ko:
761.0658.7, Akt2ko: 838.8637.6). The proportion of type II
fibers was reduced in Akt1ko but not in Akt2ko (WT: 64.861.2%,
Akt1ko: 55.661.4%, Akt2ko: 65.860.9%; WT vs. Akt1ko
p,0.05). Type I fiber CSA tended to be smaller in soleus muscle
Figure 1. Effects of ActRIIB inhibition on Akt levels in
gastrocnemius muscle. (A) Phosphorylated Akt (Ser473), total Akt1/
2/3, and b-actin levels after 10 weeks of vehicle- (Veh) or ActRIIB-mFc
treatment. (B) Total and p-Akt levels relative to b-actin. *p,0.05 vs.
vehicle.
doi:10.1371/journal.pone.0012707.g001
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the number of type I fibers was not significantly affected
(Figures 5C). Type II fibers were smaller in the soleus muscle of
Akt1ko mice (Figure 5D–E, p,0.05) and the number of type II
fibers was reduced (Figures 5F, p,0.05). ActRIIB-mFc increased
soleus CSA (WT: 1.8860.18, Akt1: 1.7560.15, Akt2: 1.946
0.17 mm
2,p ,0.05) but did not change the total number of fibers
(WT: 828.8629.2, Akt1: 854.3674.7, Akt2: 860.5642.2). Ac-
tRIIB-mFc did not alter the fiber composition of soleus muscles in
WT, Akt1ko and Akt2ko mice (Percent Type II in WT:
61.562.4%, Akt1ko: 54.763.3%, Akt2ko: 65.661.7%). The
mean CSA of type I and type II fibers was significantly altered
with ActRIIB-mFc treatment (Figure 5B, 5E p,0.01 for both) and
the distribution shifted to the right in all genotypes following
ActRIIB-mFc treatment (Figure 5A, 5D). However, the total
numbers of type I and type II fibers were not affected by ActRIIB-
mFc (Figure 5C, 5F).
Effects of Akt deficiency and ActRIIB blockade on muscle
function
Forelimb grip strength was reduced in Akt1ko and Akt2ko
compared to WT (Figure 6A, p,0.01). We subjected WT, Akt1ko
and Akt2ko mice to an endurance treadmill exercise test until
fatigue. There were no apparent differences in the distance run
(Figure 6B), or work done during exercise among the genotypes
(Figure 6C). ActRIIB-mFc increased grip strength across geno-
types (Figure 6A, p=0.0024). Despite a clear trend we observed a
non-significant decrease in distance run (Figure 6B) and work done
(Figure 6C) during endurance testing in WT and Akt1ko mice with
treatment.
Muscle contraction was measured in EDL muscles ex vivo.
Maximum twitch force was decreased in Akt1ko and Akt2ko as
compared to WT (Figure 7A, p,0.01 for both). However, there
was no significant difference in the twitch dynamics among WT,
Akt1ko or Akt2ko EDL muscles (Figure 7B). The time to peak
contraction (CT) was similar across genotypes (WT: 35.063.3,
Akt1ko: 32.062.5, Akt2ko: 28.862.3 msec). The time to half
maximum force (KRT) was not affected by genotype (WT:
32.561.6, Akt1ko: 31.062.3, Akt2ko: 27.561.6 msec). The
maximum tetanic force was decreased in Akt1ko and Akt2ko
(Figure 7C, p,0.01), but tetanus dynamics were not different
(Figure 7D).
ActRIIB-mFc increased the EDL twitch force across genotypes
(Figure 7A, p,0.0001). CT was not affected by ActRIIB-mFc
(WT: 33.861.8, Akt1ko: 32.062.5, Akt2ko: 27.561.6 msec). In
contrast, KRT was decreased by ActRIIB-mFc across genotypes
(WT: 26.361.8, Akt1: 26.061.6, Akt2: 25.061.9 msec, p,0.01),
while the maximum tetanic force was increased by ActRIIB-mFc
treatment (Figure 7C, p,0.0001).
Effect of Akt deficiency and ActRIIB blockade on
expression of atrophy-related genes
We detected no significant effect of Akt1 or Akt2 deficiency on
the expression of atrophy-related E3-ubiquitin ligases, MAFbx/
atrogin-1 and MuRF1 (Figure S1). Inhibition of ActRIIB signaling
resulted in non-significant decrease in expression of MAFbx and
MuRF1 in WT mice, and significant decrease in Akt2ko mice
(Figure S1, p,0.01 and p,0.05 respectively).
Effects of Akt deficiency and ActRIIB blockade on Akt
signaling
WT, Akt1ko, and Akt2ko gastrocnemius lysates were blotted for
expression of Akt signaling proteins (Figure 8A). Total Akt1 and
Figure 2. Effects of Akt deficiency and ActRIIB inhibition on
body composition. Effects of genotype and ActRIIB-mFc treatment
(Rx, black bar) or vehicle (Veh, white bar) in wild-type (WT), Akt1
knockout mice (Akt1 KO), and Akt2 knockout mice (Akt2 KO) on
(A) body weight, (B) percentage lean, (C) percentage fat. Data are mean
+/2 SEM, n=5. + P,0.05 vs. WT treated with vehicle; ++ P,0.01 vs. WT
treated with vehicle; *P,0.05 vs. same genotype treated with vehicle;
**P,0.01 vs. same genotype treated vehicle.
doi:10.1371/journal.pone.0012707.g002
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PLoS ONE | www.plosone.org 3 September 2010 | Volume 5 | Issue 9 | e12707Figure 3. Effects of Akt deficiency and ActRIIB inhibition on skeletal muscle weights. Effects of genotype and ActRIIB-mFc treatment (Rx,
black bar) or vehicle (Veh, white bar) in wild-type (WT), Akt1 knockout mice (Akt1 KO), and Akt2 knockout mice (Akt2 KO) on (A) Extensor digitorum
longus, (B) Gastrocnemius (C) Quadriceps, (D) Tibialis Anterior, (E) Soleus, and (F) Heart. Data are mean +/2 SEM, n=5; + P,0.05 vs. WT treated with
vehicle; ++ P,0.01 vs. WT treated with vehicle; +++P,0.0001 vs. WT treated with vehicle. *P,0.05 vs. same genotype treated with vehicle **P,0.01
vs. same genotype treated with vehicle; ***P,0.0001 vs. same genotype treated with vehicle.
doi:10.1371/journal.pone.0012707.g003
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PLoS ONE | www.plosone.org 4 September 2010 | Volume 5 | Issue 9 | e12707Figure 4. Effects of Akt deficiency and ActRIIB inhibition on EDL fiber size and distribution. (A) Effects of genotype and ActRIIB-mFc
treatment on EDL fiber cross-sectional area distributions. Wild-type (WT, red), Akt1 knockout mice (Akt1 KO, green), Akt2 knockout mice (Akt2 KO,
blue), ActRIIB-mFc -treated WT (WT Rx, red-dashed), ActRIIB-mFc -treated Akt1 KO (Akt1 KO Rx, green dashed), and ActRIIB-mFc -treated Akt2 KO
(Akt2 KO Rx, blue dashed) EDL fiber distributions; n$792 fibers per group; (B) Single fiber cross sectional areas per genotype (Veh, white bar) and
treatment (Rx, black bar); (C) Number of fibers in the EDL. Data are mean +/2 SEM, n=5; +++P,0.0001 vs. WT treated with vehicle; ***P,0.0001 vs.
same genotype treated with vehicle.
doi:10.1371/journal.pone.0012707.g004
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PLoS ONE | www.plosone.org 5 September 2010 | Volume 5 | Issue 9 | e12707Figure 5. Effects of Akt deficiency and ActRIIB inhibition on soleus fiber size and distribution. (A) Effects of genotype and ActRIIB-mFc
treatment on soleus type I and type II fiber cross-sectional area distributions. Wild-type (WT, red), Akt1 knockout mice (Akt1 KO, green), Akt2
knockout mice (Akt2 KO, blue), ActRIIB-mFc -treated WT (WT Rx, red-dashed), ActRIIB-mFc -treated Akt1 KO (Akt1 KO Rx, green dashed), and ActRIIB-
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WT whereas phospho-Akt levels were similar across genotypes.
Total glycogen synthase kinase-3 (GSK-3) levels in Akt mutant
lysates were comparable to WT, but phosphorylated GSK-3 levels
were reduced in Akt1ko and Akt2ko. Mammalian target of
rapamycin (mTOR) levels were similar across genotypes, while
phosphorylated S6 kinase (S6K) tended to be variable among WT,
Akt1ko and Akt2ko (Figure 8A). Levels of phosphorylated S6
ribosomal protein were undetectable in both Akt1ko and Akt2ko,
and total S6 levels were decreased. Glycogen content was
significantly lower in Akt1ko and Akt2ko compared to WT
(Figure 8B, p,0.0001 in Akt1ko and Akt2ko versus WT). ActRIIB
inhibition increased Akt1 and Akt2 in WT, and Akt2 in Akt1ko
mice. We did not detect changes in phosphorylated Akt,
phosphorylated GSK-3, total GSK-3, mTOR, and phosphorylat-
ed S6K in response to ActRIIB inhibition. Levels of phosphor-
ylated S6 were increased in response to ActRIIB inhibition in WT,
whereas total S6 levels were not altered substantially. Glycogen
content was significantly increased by ActRIIB inhibition in WT
(p,0.05), and tended to increase in Akt1ko and Akt2ko mice
(Figure 8B).
Discussion
Akt plays a pivotal role in mediating the responses to insulin and
growth factors [1,27]. Akt1 and Akt2 are highly expressed in
insulin-sensitive tissues. Constitutive expression of Akt1 in L6
myoblasts promotes glucose and amino acid uptake and protein
synthesis [28]. Overexpression of Akt2, but not Akt1, stimulates
C2C12 muscle cell differentiation, suggesting that Akt1 and Akt2
isoforms are necessary for optimal muscle growth [29]. Mice
lacking Akt1 are smaller and have been reported to show a
decrease in muscle size compared with wild-type mice [6,7,8].
Akt2 deficient mice exhibit a diabetic phenotype, associated with
reduced glucose uptake in the EDL but not the soleus muscle,
suggesting a fiber type specific insulin resistance (15). Mice with
Akt1/Akt2 deficiency develop multiple developmental defects and
severe muscle atrophy, indicating that both Akt isoforms
contribute to the determination of muscle size. However, detailed
analyses of the effects of Akt1 and Akt2 deficiency on body
composition, muscle structure and function are lacking.
Our studies revealed differential effects of Akt1 and Akt2
deficiency on body composition and skeletal muscle. In agreement
with previous reports, Akt1ko mice were smaller, and displayed
proportional decreases in body and lean mass compared to wild-
type mice [6,7,8]. In contrast, Akt2ko mice weighed less than wild-
type mice, an effect explained mainly by a decrease in body fat.
Akt1ko mice had significant decreases in the weights of
gastrocnemius, EDL, and quadriceps, i.e. muscles composed
mainly of type II fibers [30]. By examining the histology of EDL,
we found the Akt1 deficiency was associated with a significant
decrease in the cross-sectional area of fibers. In contrast to EDL,
Akt1 deficiency did not change the weight of soleus muscle, which
is composed of both type I and type II fibers. Nonetheless, Akt1
deficiency decreased the number of type II fibers in soleus muscle.
Thus, Akt1 is essential for the determination of the size and
number of type II fibers. Our results are in agreement with Easton
et al. who demonstrated that cardiomyocytes from Akt1ko mice
have smaller CSA [8]. Akt2 deficiency resulted in significant
reductions the weights of EDL and gastrocnemius, whereas the
weight of soleus muscle was increased relative to wild-type mice.
The reduction in EDL weight in Akt2ko was explained, at least
partly, by a reduction in fiber cross-sectional area. The reasons for
the increase in soleus muscle weight in Akt2ko mice are unknown.
There were no apparent changes in the fiber cross-sectional area
or number of fibers counted at the mid-section of the soleus
muscle. However, it is possible that an increase in soleus muscle
triglyceride or extracellular matrix that were not measured in our
study may have played a role in the increase in soleus weight
observed in Akt2ko mice.
Overexpression of constitutively active Akt1 or Akt2 in muscle
results in increased levels of phosphorylated S6K and glycogen
content [31]. In agreement with these findings, we found that Akt1
and Akt2 deficient animals have decreased phosphorylated S6
levels, a marker of S6K activity, and decreased levels of
phosphorylated GSK-3 and glycogen content.
While Akt is important for the development of muscle size and
function, we found that the hypertrophy resulting from ActRIIB
inhibition with ActRIIB-mFc was not dependent on either Akt1 or
Akt2 isoforms. Similar to wild-type mice, ActRIIB-mFc treatment
increased the mean EDL fiber cross-sectional area and shifted the
fiber distribution to the right in Akt1ko and Akt2ko mice,
consistent with type II fiber hypertrophy [15,32,33]. ActRIIB-
mFc treatment induced type I and type II fiber hypertrophy in the
soleus muscle. This result is in agreement with a recent study in
which ACE031 (the humanized analogue of ActRIIB-mFc)
treatment increased the mean fiber cross-sectional area in
plantaris, a predominantly type II muscle, and as well as type I
and type II fibers in the soleus muscle [26].
Our results suggest that the increase in muscle mass resulting
from ActRIIB-mFc treatment is specialized for strength. Forelimb
grip strength and EDL twitch and tetanic contractions were
increased by ActRIIB-mFc in wild-type as well as Akt1ko and
Akt2ko mice. However, ActRIIB-mFc treatment did not improve
the distance run or endurance during treadmill exercise. It is
unclear whether a longer treatment would reveal distinct effects of
Akt deficiency on exercise.
In vitro treatment with the ActRIIB ligand, myostatin, has been
shown to increase the expression of atrophy-mediating E3-
ubiquitin ligases, MAFbx/Atrogin-1 and MuRF1 [21,34]. Addi-
tionally, overexpression of Akt in cultured myotubes inhibits
glucocorticoid-induced expression of MAFbx [35]. Consistent with
these observations, in vivo ActRIIB inhibition increased Akt protein
levels and decreased mRNA expression of MAFbx and MuRF1 in
gastrocnemius, suggesting inhibition of muscle atrophy.
In summary, our results demonstrate that Akt1 and Akt2 are
important regulators of muscle size and function; however, neither
Akt1 nor Akt2 isoforms are essential for the response to ActRIIB
inhibition. In support of our findings, Sartori et al. found that
ActRIIB inhibition in muscles where Akt was constitutively active
(c.a.Akt) led to even greater hypertrophy than c.a.Akt alone
suggesting that ActRIIB and Akt promote muscle hypertrophy
through distinct but connected pathways [10]. We speculate that
S6K plays a key role in ActRIIB-mFc induced hypertrophy
independent of PI3K/Akt as was the case in the response to
mechanical stretch in cultured myotubes [36]. Future studies in
mFc -treated Akt2 KO (Akt2 KO Rx, blue dashed) on soleus type I fiber distribution; n$393 fibers per group. (B) Type I single fiber cross sectional area
(CSA) per genotype (Veh, white bar) and treatment (Rx, black bar); (C) Number of type I fibers in the soleus; (D) Soleus type II fiber distribution; n$458
fibers per group. (E) Type II single fiber CSA per genotype and treatment; (F) Number of type II fibers in the soleus; Data are mean +/2 SEM, n=5;
+P,0.05 vs. WT treated with vehicle; *P,0.05 vs. same genotype treated with vehicle.
doi:10.1371/journal.pone.0012707.g005
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potential interactions between Akt and ActRIIB, and the
implications for growth and function of muscle.
Methods
Immunoblotting
Gastrocnemius muscle was homogenized in lysis buffer
containing 50 mM Tris?HCl (pH 7.4), 250 mM mannitol,
50 mM NaF, 1 mM sodium pyrophosphate, 1 mM benzamidine,
and 1 mM phenylmethylsulfonyl fluoride with 0.5% (wt/vol)
Triton X-100, supplemented with complete protein inhibition
cocktail tablet from Roche (Penzberg, Germany) as described
previously [37]. Protein extracts (30 mg) were separated by 4–12%
NuPAGE Bis-Tris gel (Invitrogen) and transferred to nitrocellulose
membranes with semidry transfer cells (Bio-Rad Laboratories,
Hercules, CA). After 1 h of blocking with Tris-buffered saline with
0.1% (vol/vol) Tween 20 containing 3% (wt/vol) nonfat dried
milk, membranes were incubated with a polyclonal antibody
against phosphorylated (Ser473) Akt and Akt1/2/3 (Santa Cruz).
Additionally blotted for Akt1, Akt2, phosphorylated (Ser9, Ser21)
Glycogen synthase kinase-3, mammalian target of rapamycin,
phosphorylated (Thr389) S6 kinase, phosphorylated (Ser240/244)
S6 ribosomal protein, S6 ribosomal protein, glyceraldehyde-3-
phosphate dehydrogenase, and b-actin (Cell Signaling). The
signals were detected with enhanced chemiluminescence (ECL,
Amersham), and film autoradiograms were analyzed with laser
densitometry and Photoshop CS3 (Adobe).
Animals and treatment
All animal work was reviewed and approved by the Institutional
Animal Care and Use Committee of the University of Pennsylvania
School of Medicine (Protocol # 701656). Eight-week-old male
wild-type (WT) C57BL/6J mice(Jackson Laboratories, BarHarbor,
ME) and Akt1ko [7] and Akt2ko mice [11] were housed (n=5 per
cage) under a 12: 12-h light-dark cycle (light on at 0700) and an
ambient temperature of 22uC, and allowed free access to water
and chow diet. ActRIIB-mFc (also termed RAP031, 10 mg/kg)
provided by Acceleron Pharmaceuticals, Cambridge, MA) was
injected intraperitoneally twice weekly for 10 weeks [15]. The
vehicle was phosphate-buffered saline (PBS). Mice were fed regular
chow diet (LabDiet, Richmond, IN, # 5001, containing 4.5% fat,
49.9% carbohydrate, 23.4% protein; 4 kcal/g). Food intake was
measured weekly, and body composition was assessed prior to
treatment and 10 weeks later with nuclear magnetic resonance
(NMR) (Echo Medical Systems, Houston, TX) [15,37].
Treadmill and grip strength
ActRIIB-mFc or vehicle-treated mice were acclimatized to a
modular treadmill connected to an open circuit indirect
calorimeter (CLAMS, Columbus Instruments, Columbus, OH).
After 10 weeks of treatment, the mice were deprived of food for
5 hours in the morning, and underwent forced exercise on the
treadmill (angle 10u, 15 min at 10 meters/min and then
Figure 6. Effects of Akt deficiency and ActRIIB inhibition on in
vivo muscle function. Effects of genotype (Veh, white bar) and
ActRIIB-mFc treatment (Rx, black bar) in wild-type (WT), Akt1 knockout
mice (Akt1 KO), and Akt2 knockout mice (Akt2 KO) on (A) forelimb grip
strength; (B) distance ran during an endurance exercise protocol;
(C) work done during an endurance protocol. Data is mean +/2 SEM,
n=5;+ P,0.05 vs. WT treated with vehicle; ++ P,0.01 vs. WT treated
with vehicle. *P,0.05 vs. same genotype treated with vehicle.
doi:10.1371/journal.pone.0012707.g006
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using the following equation: mg (mkcosh+sinh)*[coshdx+sinhdy]
where m=mass, g=9.81 m/s
2, mk=0.987, h=angle of treadmill
incline, dx=horizontal distance, dy=vertical distance.
The muscle strength in the forelimbs was measured with a grip
meter (TSE; Bad Hamburg, Germany) as previously described
[15]. Briefly, mice were trained to grasp a horizontal metal bar
while being pulled by their tail and the force was detected by a
sensor. Ten measurements were determined for each mouse and
averaged.
EDL contraction
The mice were euthanized with carbon dioxide, muscles were
dissected and weighed, and contraction of the extensor digitorum
longus (EDL) muscle was analyzed ex vivo. Physiological measure-
ments, including contraction time, half-relaxation time, peak
isometric twitch force, and peak isometric tetanic force were
analyzed in freshly dissected EDL muscles as previously described
[38]. Briefly, muscles were stimulated in Ringer’s solution
composed of 100 NaCl mM, 4.7 KCl mM, 3.4 mM CaCl2,
1.2 mM KH2PO4, 1.2 mM MgSO4, 25 mM HEPES, and
5.5 mM D-glucose. Muscle length was adjusted to obtain the
maximal twitch response, and this length was measured and
recorded as optimal length. Peak twitch and tetanus forces were
obtained from three maximal contractions (120-Hz stimulation
frequency, 500-ms stimulation duration).
Histology
At the end of the physiological studies, EDL and soleus muscles
were flash-frozen in isopentane cooled in liquid nitrogen and
Figure 7. Effects of Akt deficiency and ActRIIB inhibition on EDL contraction. Effects of genotype (Veh, white bar) and ActRIIB-mFc
treatment (Rx, black bar) on EDL ex vivo force generation. (A) Peak twitch force (mN) in wild-type (WT), Akt1 knockout mice (Akt1 KO), and Akt2
knockout mice (Akt2 KO); (B) Representative twitch recordings; (C) Peak tetanic force (mN). (D) Representative tetanic recordings. Data in (A, C) are
mean +/2 SEM, n=5; + P,0.05 vs. WT treated with vehicle; ++ P,0.01 vs. WT treated with vehicle. *P,0.05 vs. same genotype treated with vehicle
**P,0.01 vs. same genotype treated with vehicle.
doi:10.1371/journal.pone.0012707.g007
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were cut at mid-belly of the EDL muscle using a cryostat at
221uC and placed onto glass slides (Superfrost/Plus, Fisher
Scientific). Single-fiber cross-sectional area (CSA) and distribution
were determined in images from tissue sections immunostained for
laminin [39]. Photomicrographs were taken using an Olympus
BX51 microscope equipped with a Magnafire camera. Morpho-
metric measurements were made with Photoshop CS3 (Adobe).
Fiber data was used to calculate an average single-fiber area and
plot it as a histogram. For ease of interpretation, histograms are
presented as smoothened approximations by constructing a spline
function (GraphPad Prism), whose average value over each bar
Figure 8. Effects of ActRIIB inhibition on Akt signaling and glycogen content. (A) Immunoblots of vehicle (Veh) and ActRIIB-mFc treated
(Rx) wild-type (WT), Akt1 knockout (Akt1ko), and Akt2 knockout (Akt2ko) gastrocnemius lysates. P: phospho-specific antibody (B) Effects of genotype
(Veh, white bar) and ActRIIB-mFc treatment (Rx, black bar) on quadriceps glycogen content (mg glycogen per g muscle). +++P,0.0001 vs. WT Veh,
*p,0.05 vs. vehicle.
doi:10.1371/journal.pone.0012707.g008
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was counted per muscle section. Type I and type II fibers were
distinguished through metachromatic ATPase method [40,41].
Glycogen content
Quadriceps muscles were dissected, weighed, and flash frozen in
liquid nitrogen. Samples were homogenized in 0.03 N HCl. The
homogenate (100 ml) was mixed with 400 ml of 1.25 N HCl and
heated for 1 h at 100uC. Samples were centrifuged at 14,000 rpm,
and 10 ml of supernatant was mixed with 1 ml of glucose oxidase
reagent (Sigma). After a 10-min incubation at 37uC, the
absorbance was read at 505 nm. A standard curve using glycogen
type III obtained from rabbit liver (Sigma) was also simultaneously
analyzed to determine the final liver glycogen concentrations.
Statistical analysis
The effects of genotype and ActRIIB-mFc treatment on various
parameters were analyzed by ANOVA, and pair-wise differences
were determined with student’s t-test.
Supporting Information
Figure S1 Effects of Akt deficiency and ActRIIB inhibition on
MAFbx and MuRF1 expression. Effects of genotype and ActRIIB-
mFc treatment (Rx, black bar) or vehicle (Veh, white bar) in wild-
type (WT), Akt1 knockout mice (Akt1ko), and Akt2 knockout mice
(Akt2ko) on MAFbx (Fbxo32) and MuRF1 (Trim63) expression.
Expression values are normalized to phosphoriboprotein (36B4;
Rplp0). Data are mean 6 SEM, n=5. **P,0.01 vs. same
genotype treated vehicle.
Found at: doi:10.1371/journal.pone.0012707.s001 (0.13 MB TIF)
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